Presentation is loading. Please wait.

Presentation is loading. Please wait.

Dermatology Drug for plaque psoriasis. Plaque Psoriasis that the disease may result from a disorder in the immune system. The immune system makes white.

Similar presentations


Presentation on theme: "Dermatology Drug for plaque psoriasis. Plaque Psoriasis that the disease may result from a disorder in the immune system. The immune system makes white."— Presentation transcript:

1 Dermatology Drug for plaque psoriasis

2 Plaque Psoriasis that the disease may result from a disorder in the immune system. The immune system makes white blood cells that protect the body from infection. In psoriasis, the T cells (a type of white blood cell) abnormally trigger inflammation in the skin. These T cells also cause skin cells to grow faster than normal and to pile up in raised patches on the outer surface of the skin.

3 FACTOR TRIGGER PSORIASIS Those with a family history of psoriasis have an increased chance of having the disease. Some people carry genes that make them more likely to develop psoriasis. Certain factors may trigger psoriasis, such as injury to the skin, sunlight, stress, alcohol, HIV infection, smoking, and certain drugs

4 SIGINS AND SYMPTOMS An individual with plaque psoriasis usually has patches of red, raised, scaly areas on the skin that may itch or burn. The patches are usually found on the knees, elbows, trunk, or scalp

5

6

7

8 Dermatology Drug Drug Name: Stelara (ustekinumab) Company: Centocor Ortho Biotech Aproval Status: Approved September 2009 Treatment Area: plaque psoriasis

9 What exactly is STELARA made of? The active ingredient in STELARA ® is called ustekinumab. The other ingredients are sucrose, L- histidine, and polysorbate 80.

10 Mechanism of Action Stelara (ustekinumab) is a human IgG1k monoclonal antibody that binds with high affinity and specificity to the p40 protein subunit used by both the interleukin (IL)-12 and IL-23 cytokines. IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation

11

12 TYPE OF FORMULATION: Stelara is supplied as a solution for subcutaneous injection. The recommended initial dose of the drug is as follows: For patients weighing ≤100 kg (220 lbs): 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks. For patients weighing >100 kg (220 lbs): 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks. The 45 mg dose was also shown to be efficacious in this population. However, 90 mg resulted in greater efficacy in these subjects

13 Dosing Schedule

14 STELARA ® Results Everyone responds to treatments differently. However, STELARA ® patients saw at least 75% clearer skin at 12 weeks,

15

16

17 Cautions and contraindications if your doctor feels that you are at risk for TB, are pregnant or plan to become pregnant. are breast-feeding or plan to breast-feed. It is thought that STELARA ® passes into your breast milk ever had an allergic reaction to STELARA

18 Side Effects increase your risk for certain types of cancer Serious Allergic Reactions Nasopharyngitis Upper respiratory tract infection Headache Fatigue Diarrhea

19 Everyone look for healthy and nice skin

20 Thanks for your attention Prepared by : Rema’ Atyeh


Download ppt "Dermatology Drug for plaque psoriasis. Plaque Psoriasis that the disease may result from a disorder in the immune system. The immune system makes white."

Similar presentations


Ads by Google